Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:17:17.712Z.
Calculation as of: 2026-10-06T18:17:17.712Z.
Quote observation: 2026-10-06T18:14:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc00e8cb63dba40c56ed5fb80588e73c180b52fe93b8081d2416c5f575d95e45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Insight Molecular Diagnostics Inc.
Market Cap
$112.21M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $112.21M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $111.85M | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.81M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.41M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.14M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.27M | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.12M | N/A |
| Genelux Corporation (GNLX)vs › | $114.34M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
